Roche Holding AG
π¨πSwitzerland
- Country
- π¨πSwitzerland
- Ownership
- Public
- Established
- 1896-01-15
- Employees
- 103.6K
- Market Cap
- $270.5B
- Website
- http://www.roche.com
- Introduction
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
A Study of RoActemra/Actemra and, if Initially Inadequately Responded to RoActemra/Actemra, Followed by MabThera/Rituxan in Patients With Rheumatoid Arthritis
Phase 3
Completed
- Conditions
- Rheumatoid Arthritis
- Interventions
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2015-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 519
- Registration Number
- NCT01332994
An Observational Study of Avastin (Bevacizumab) in Combination With Chemotherapy in Patients With Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- First Posted Date
- 2011-04-11
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 423
- Registration Number
- NCT01333007
A Study of Danoprevir/Ritonavir and Copegus With RO5024048 and/or Pegasys in Patients With Chronic Hepatitis C
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 381
- Registration Number
- NCT01331850
A Study of Tocilizumab in Comparison to Etanercept in Participants With Rheumatoid Arthritis and Cardiovascular Disease Risk Factors
- First Posted Date
- 2011-04-08
- Last Posted Date
- 2017-07-13
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 3080
- Registration Number
- NCT01331837
- Locations
- πΊπΈ
Emory Uni ; Division of Rheumatology, Atlanta, Georgia, United States
πΊπΈApex Medical Research, AMR, Inc., Chicago, Illinois, United States
πΊπΈColumbus Arthritis Center, Columbus, Ohio, United States
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Phase 3
Completed
- Conditions
- Non-Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2011-04-05
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 643
- Registration Number
- NCT01328951
A Study of RO4905417 in Patients With Non ST-Elevation Myocardial Infarction (Non-STEMI) Undergoing Percutaneous Coronary Intervention
Phase 2
Completed
- Conditions
- Myocardial Infarction
- Interventions
- First Posted Date
- 2011-04-01
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 532
- Registration Number
- NCT01327183
A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF
- First Posted Date
- 2011-03-31
- Last Posted Date
- 2017-08-16
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 28
- Registration Number
- NCT01326962
- Locations
- πΈπ¦
Heraa General Hospital; Rheumatology, Makkah, Saudi Arabia
πΈπ¦King Abdulaziz University Hospital, Jeddah, Saudi Arabia
πΈπ¦King Fahad Specialist Hospital; Oncology, Dammam, Saudi Arabia
A Study of RO5083945 in Combination With FOLFIRI Versus FOLFIRI Plus Cetuximab or FOLFIRI Alone as Second Line Treatment in Patients With Metastatic Colorectal Cancer
- First Posted Date
- 2011-03-30
- Last Posted Date
- 2022-11-17
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 169
- Registration Number
- NCT01326000
A Study of Dalcetrapib in Patients Hospitalized For An Acute Coronary Syndrome (Dal-ACUTE)
- First Posted Date
- 2011-03-25
- Last Posted Date
- 2019-07-30
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 300
- Registration Number
- NCT01323153
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2011-03-22
- Last Posted Date
- 2016-09-07
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 609
- Registration Number
- NCT01319877
Β© Copyright 2025. All Rights Reserved by MedPath